Clinical Microbiology (2026 IMCU)

Only available as part of a package

Learning Objectives:

Upon completion, participants will be able to:
- describe the clinical applications, strengths, and limitations of modern diagnostic technologies, including multiplex syndromic panels, MALDI-TOF mass spectrometry, and next-generation sequencing (NGS), to select the most appropriate test for complex infectious cases.
- apply the 2024 IDSA/ASM diagnostic stewardship guidelines for optimal specimen collection (tissue vs. swabs) and interpretation, distinguishing between colonization/contamination and true infection, particularly in blood and urine cultures.
- incorporate recent practice-changing evidence into clinical decision-making, including the use of novel antimicrobial agents for resistant pathogens (CRAB, MRSA), optimized treatment durations, oral step-down therapy for bacteremia, and updated vaccination strategies.

Patrick J. Kenney, DO, FACOI (he/him/his)

Vice Chair and Fellowship Program Director, Department of Infectious Diseases

Cleveland Clinic Florida

Patrick J. Kenney, D.O., F.A.C.O.I. Vice Chair, Department of Infectious Diseases, Cleveland Clinic Florida has been in clinical practice since 2013. Dr. Kenney completed his internal medicine training at Broward Health Medical Center in Fort Lauderdale, FL and his fellowhip in infectious diseases at Morsani College of Medicine at the University of South Florida in Tampa, FL. He is the newly appointed program director for the Infectious Disease fellowship program at the Cleveland Clinic Florida in Weston, FL. Dr. Kenney cares for patients across all aspects of the specialty in both the inpatient and outpatient setting. He is clinical adjunct faculty at Florida Atlantic University Charles E. Schmidt College of Medicine, Ross University College of Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine at Nova Southeastern University, and St. George's University College of Medicine. His clincal interests include virology particularly HIV as well as transplant infectious diseases.

The faculty member, for this activity, has no relevant relationships with ineligible companies to disclose.